SEC Form SC 13G filed by iCAD Inc.

3/15/23 3:15:23 PM ET

Medical/Dental Instruments

Health Care

Get the next $ICAD alert in real time by email

SC 13G 1 ICAD.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 iCAD Inc (Name of Issuer) Common (Title of Class of Securities) 44934S206 (CUSIP Number) March 10, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ X ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 44934S206 13G Page 2 of 6 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Pura Vida Investments, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,277,214* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,277,214* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,277,214* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.02%** 12. TYPE OF REPORTING PERSON (see instructions) IA CUSIP No. 44934S206 13G Page 3 of 6 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Efrem Kamen 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,277,214* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,277,214* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,277,214* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.02%** 12. TYPE OF REPORTING PERSON (see instructions) IN, HC CUSIP No. 44934S206 13G Page 4 of 6 Pages Item 1. (a) Name of Issuer iCAD, Inc. (b) Address of Issuers Principal Executive Offices 98 Spit Brook Road, Suite 100 Nashua, NH 03062 Item 2. (a) Name of Person Filing Pura Vida Investments, LLC Efrem Kamen (collectively, the "Filers"). (b) The address of the principal place of the Filers is located at: Pura Vida Investments, LLC 512 West 22nd Street, 7th Floor New York, NY 10011 (c) For citizenship of Filers, see Item 4 of the cover sheet for each Filer. (d) Title of Class of Securities Common (e) CUSIP Number 03837C106 Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1) (ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1) (ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). CUSIP No. 44934S206 13G Page 5 of 6 Pages Item 4. Ownership. (a) Amount beneficially owned: Pura Vida Investments LLC 1,277,214* shares Efrem Kamen 1,277,214* shares (b) Percent of class: Pura Vida Investments LLC 5.02%* Efrem Kamen 5.02%* (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote Pura Vida Investments LLC 1,277,214* shares Efrem Kamen 1,277,214* shares (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of Pura Vida Investments, LLC 1,277,214* shares Efrem Kamen 1,277,214* shares *Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. Efrem Kamen serves as the managing member of PVI. By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the Pura Vida Master Fund and the Managed Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Persons pecuniary interest therein. Item 5. Ownership of Five Percent or Less of a Class. N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A CUSIP No. 44934S206 13G Page 6 of 6 Pages Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Exhibits. Exhibit A Joint Filing Agreement. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 14, 2023 Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member

Get the next $ICAD alert in real time by email

Date

Price Target

Rating

Analyst

1/18/2022

Buy → Neutral

Guggenheim

1/5/2022

$22.00 → $16.00

Outperform

Oppenheimer

11/10/2021

$22.00 → $18.00

Market Outperform

JMP Securities

SEC Form SC 13G filed by iCAD Inc.

Chat with this insight

Recent Analyst Ratings for $ICAD

$ICAD SEC Filings

SEC Form 10-Q filed by iCAD Inc.

iCAD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form 10-Q/A filed by iCAD Inc.

$ICAD Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

SEC Form SC 13G filed by iCAD Inc.

$ICAD Market Insights

Live Market Insights

iCAD to Highlight Research On Potential Of Its AI Algorithm In Breast Cancer Risk Assessment At SIIM 2024

12 Health Care Stocks Moving In Monday's After-Market Session

icad Q1 Adj $(0.05) Beats $(0.06) Estimate, Sales $4.95M Beat $4.44M Estimate

$ICAD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

icad downgraded by Guggenheim

Oppenheimer reiterated coverage on icad with a new price target

JMP Securities reiterated coverage on icad with a new price target

$ICAD Press Releases

Fastest customizable press release news feed in the world

iCAD Reports Financial Results for Third Quarter Ended September 30, 2024

iCAD's ProFound Detection Version 4.0 Gains FDA Clearance

iCAD to Report Third Quarter 2024 Financial Results on November 13, 2024

$ICAD Leadership Updates

Live Leadership Updates

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member

iCAD Strengthens Leadership Team with Appointment of Chief Financial Officer and New Senior Executives

$ICAD Financials

Live finance-specific insights

$ICAD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

iCAD Reports Financial Results for Third Quarter Ended September 30, 2024

iCAD to Report Third Quarter 2024 Financial Results on November 13, 2024

iCAD Reports Financial Results for Second Quarter Ended June 30, 2024

SEC Form 4 filed by Director Sassine Andy

SEC Form 4 filed by Director Patel Rakesh

SEC Form 4 filed by Wood Susan Alyson

Recent Analyst Ratings for
$ICAD

$ICAD
SEC Filings

$ICAD
Large Ownership Changes

$ICAD
Market Insights

$ICAD
Analyst Ratings

$ICAD
Press Releases

$ICAD
Leadership Updates

$ICAD
Financials

$ICAD
Insider Trading